PRESURV Late-Line Therapies

Treatment guidelines typically provide clear recommendations for first- and second-line therapies across most cancer types. However, these guidelines are often lacking recommendations for third- or later-line treatments. This also holds for non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), where no standardized recommendations are currently available for later lines of therapy.

The study aim is to use machine learning to predict overall survival and disease progression (including the development of metastases) in NSCLC and CRC patients undergoing third-line or later systemic therapy. The focus is on systemic treatments. The study will also explore the heterogeneity of therapies used in later lines and targets to identify common treatments sequences and patterns to predict their impact on survival.

The study will use nationwide cancer registry data from the center for cancer registry data, which includes comprehensive information on cancer diagnoses, staging, therapies and outcomes. This data will be analyzed in Frankfurt, with the aim of deriving guideline recommendations and thereby contributing to improved clinical care in the context of later line systemic anti-cancer treatment.